MedPath

An open label, randomized control study for the comparison of effectiveness between biguanides and Dipeptidyl peptidase-4 (DPP-4) inhibitor in people with type 2 diabetes

Not Applicable
Conditions
type 2 diabetes
Registration Number
JPRN-UMIN000010385
Lead Sponsor
Kanazawa University Graduate School of Medical Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Not provided

Exclusion Criteria

1.Hypersensitivity to or contraindication of biguanides and alogliptin 2.Type 1 diabetes, gestational diabetes mellitus, secondary diabetes 3.Medical history and/or complication of diabetic ketoacidosis 4.Medical history and/or complication of severe hypoglycemia 5.Severe infection, before and after surgery, patients with severe trauma 6.Patients treated with metformin or alogliptin within 4 weeks before the start of treatment 7.Patients introduced or those undergoing systemic administration of steroids 8.unstable glycemic control 9.Patients with severe renal impairment, including patients requiring hemodialysis or peritoneal dialysis (Less than more than more than Ccr 30mL / expression Cockcraft, man serum creatinine >2.5mg/dL, woman serum creatinine >2.0mg/dL) 10.Severe hypertension (systolic blood pressure > 100mmHg or diastolic blood pressure > 160mmHg) 11.The patients with severe heart disease of congestive heart failure, myocardial infarction, unstable angina within one year onset 12.Proliferative retinopathy or macular edema requiring treatment 13.History of malignancy or the treatment of malignancy within 1 year 14.Serious complications (Grade 3 classification as a guide to adverse drug reactions Ministry of Health, Labour and Welfare) 15.During pregnancy and lactation. 16.Other cases physicians sharing test was deemed inappropriate as the subject of the study or investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath